# A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

> **NCT06246695** · PHASE1 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Itraconazole capsule
- **DRUG:** Rifampicin Capsules

## Key facts

- **NCT ID:** NCT06246695
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2022-01-12
- **Final completion:** 2022-01-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246695, "A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06246695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*